Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$13.54M$13.54M+4.2% vs Q3 2023 Net Income-$11.51M-$11.51MN/M vs Q3 2023 EPS Diluted-$0.13-$0.13N/M vs Q3 2023 Operating Income-$8,290,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,960,000N/M Margins · derivedOperating margin-61.2%−42.9 pt vs Q3 2023
Net margin-85.0%−69.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end